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Development of an IgG4-Based Predictor of Endemic
Pemphigus Foliaceus (Fogo Selvagem)
Bahjat F. Qaqish1, Phillip Prisayanh2, Ye Qian2, Eugenio Andraca1, Ning Li2, Valeria Aoki3,
Gunter Hans-Filho4, Vandir dos Santos5, Evandro A. Rivitti3 and Luis A. Diaz2 for the Cooperative
Group on Fogo Selvagem Research
Fogo selvagem (FS) is mediated by pathogenic, predominantly IgG4, anti-desmoglein 1 (Dsg1) autoantibodies
and is endemic in Limao Verde, Brazil. IgG and IgG subclass autoantibodies were tested in a sample of 214 FS
patients and 261 healthy controls by Dsg1 ELISA. For model selection, the sample was randomly divided into
training (50%), validation (25%), and test (25%) sets. Using the training and validation sets, IgG4 was chosen as
the best predictor of FS, with index values above 6.43 classified as FS. Using the test set, IgG4 has sensitivity of
92% (95% confidence interval (95% CI): 82–95%), specificity of 97% (95% CI: 89–100%), and area under the curve
of 0.97 (95% CI: 0.94–1.00). The IgG4 positive predictive value (PPV) in Limao Verde (3% FS prevalence) was 49%.
The sensitivity, specificity, and PPV of IgG anti-Dsg1 were 87, 91, and 23%, respectively. The IgG4-based classifier
was validated by testing 11 FS patients before and after clinical disease and 60 Japanese pemphigus foliaceus
patients. It classified 21 of 96 normal individuals from a Limao Verde cohort as having FS serology. On the basis
of its PPV, half of the 21 individuals may currently have preclinical FS and could develop clinical disease in the
future. Identifying individuals during preclinical FS will enhance our ability to identify the etiological agent(s)
triggering FS.
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INTRODUCTION
Both non-endemic pemphigus foliaceus (PF) and its endemic
form (fogo selvagem (FS)) are characterized by subcorneal
epidermal blisters and pathogenic IgG anti-desmoglein 1
(Dsg1) autoantibodies (Beutner and Jordon, 1964; Roscoe
et al., 1985; Stanley et al., 1986; Diaz et al., 1989a). FS
patients usually live in impoverished rural areas of certain
states of Brazil where the disease is endemic (Vieira, 1937;
Diaz et al., 1989b). Strikingly, the prevalence of FS in some
states, such as Sao Paulo (Diaz et al., 1989b) and Parana
(Empinotti et al., 2006), has decreased dramatically in recent
years. An endemic form of PF has also been described in
Colombia and Tunisia (Robledo et al., 1988; Morini et al.,
1993; Abreu-Velez et al., 2003). FS exhibits a strong
association with the HLA-DRB1*0102, HLA-DRB1*0404, and
HLA-DRB1*1402 alleles (Po0.005, Relative risk: 14) and
affects people of many races and ethnic backgrounds (Moraes
et al., 1997). It has been hypothesized that a local environ-
mental agent(s), acting on genetically predisposed individuals,
triggers a crossreactive anti-Dsg1 antibody response that leads
to FS (Diaz et al., 1989b). Recent studies suggest that exposure
to hematophagous insect bites is a risk factor for FS (Lombardi
et al., 1992; Aoki et al., 2004; Diaz et al., 2004).
IgG autoantibodies in FS are isotype-restricted, and the bulk
of pathogenic anti-Dsg1 autoantibodies are predominantly IgG4
(Rock et al., 1989; Santos et al., 2001; Warren et al., 2003). In
fact, a recent study showed that progression from preclinical to
clinical stage of the disease is associated with a dramatic rise in
IgG4 anti-Dsg1 autoantibodies as determined by ELISA assays
(Warren et al., 2003). Restriction of IgG4 antibody response in
humans has been reported in patients with parasitosis
(Kurniawan et al., 1993), individuals undergoing hyposensitiza-
tion therapy for allergies (Larche et al., 2006; Rossi et al., 2007),
individuals exposed to bee stings (Aalberse et al., 1983), and
patients with autoimmune pancreatitis (Hamano et al., 2001).
IgG4 restriction of the autoimmune response has also been
reported in other autoimmune blistering diseases, although
there is limited information about their pathogenic role in skin
disease (Sitaru et al., 2007).
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Anti-Dsg1 autoantibodies in PF and FS are routinely
detected by indirect immunofluorescence (IF) techniques and
are important diagnostic markers of these diseases. The use of
PF and FS autoantibodies as predictors of disease has been
limited because of the rarity of these diseases and the
limitations of the indirect immunofluorescence assays. The
application of ELISA techniques using recombinant Dsg1 has
improved diagnostic accuracy (Amagai et al., 1999) and made
it possible to test large numbers of individuals living in
communities where FS is endemic (Hans-Filho et al., 1996).
For example, we have identified a new focus of FS in Brazil,
the Amerindian Terena reservation of Limao Verde, where the
prevalence of the disease is B3% (Hans-Filho et al., 1996).
We have reported that 30 of 31 patients along with 55% of
normal participants (n¼ 93) living in this reservation possessed
anti-Dsg1 antibodies (Warren et al., 2000; Diaz et al., 2008).
We have followed this reservation for the past 14 years and
documented the progression of FS from the preclinical stage to
disease in 11 cases. Serologically, these patients increased
their titers of anti-Dsg1 autoantibodies at the onset of their skin
disease (Warren et al., 2000), and importantly, the autoanti-
bodies during the preclinical stage bind the extracellular 5
(EC5) domain of Dsg1, whereas the pathogenic autoantibodies
recognized epitopes located on the EC1–2 domain of the
molecule during the clinical stage (Li et al., 2003).
In an effort to identify early sensitive and specific
serological markers of FS in healthy individuals, we tested
IgG and the IgG subclass anti-Dsg1 autoantibody response by
ELISA in a large number of patients and normal donors. A
rigorous statistical analysis of the data generated has
permitted us to develop an IgG4 classifier/predictor that
separates donors into one group showing immunological
features of FS and another group with features of healthy
donors. The IgG4 classifier is highly sensitive (92%) and
specific (97%). In a population with the prevalence of 3%,
that is Limao Verde, this classifier has positive predictive
value (PPV) of 49% and negative predictive value (NPV) of
99.7%. The sensitivity, specificity, and PPV of IgG anti-Dsg1
were 87, 91, and 23%, respectively, all lower than the
corresponding values for IgG4. This instrument has been
validated in two patient populations; a group of 60 Japanese
patients with PF and pemphigus vulgaris (PV) and a group
of 11 FS patients from Limao Verde where preclinical
stage sera were available. The use of this classifier tool
may facilitate the identification of individuals during the
preclinical stage of FS, thus enhancing the chances of
disclosing the etiological agent(s) triggering this human
autoimmune disease. As IgG anti-Dsg1 autoantibodies are
detected in a large number of normal individuals from
endemic areas of FS (Warren et al., 2000, 2003; Diaz et al.,
2008), the high specificity of the IgG4 anti-Dsg1 classifier
will outperform the total IgG assays when used in these
seroepidemiological studies.
RESULTS
Development of the predictor
We used data on sera from 214 FS cases (45%) and 261
healthy controls (non-cases) (55%). The results of the IgG
subclass and total IgG anti-Dsg1 ELISA of FS cases and
controls were expressed as index values. Table 1 gives
descriptive statistics of IgG index values.
Model selection and estimation of the accuracy of the
chosen model were carried out using a rigorous procedure by
splitting the data at random into training (50%), validation
(25%), and test (25%) sets. This avoids the overly optimistic
estimates of area under the curve (AUC), sensitivity, and
specificity often obtained when the same data are used for
model selection as well as for final estimation of prediction
accuracy (Hastie et al., 2001). Model parameters were
estimated from the training set, and the corresponding AUC
was estimated from the validation set.
Results from the model selection procedure, using only the
training (n¼239) and validation (n¼ 118) sets, are summar-
ized in Table 2. The AUC was used as the criterion for model
selection as it is a summary of the whole receiver-operating
characteristic curve for a given model and is not affected by
choice of a cut point as is the case for sensitivity and
specificity. The model with only x4¼ log(1þ IgG4) has an
estimated AUC of 0.961 (from the validation set). Using
additional predictors has a negligible effect on the AUC.
Thus, the model with only IgG4 was chosen as the final
model because of its parsimony and high AUC value. The
classification rule thus developed is to declare IgG4 index
values above 6.43 as cases, and values of 6.43 and below as
non-cases.
Final estimates of AUC, sensitivity and specificity of the
IgG4 classifier were obtained from the test set (n¼118). The
estimated AUC of IgG4 is 0.97 (95% confidence interval
(95% CI): 0.94–1.00), sensitivity is 92% (95% CI: 82–98%),
and specificity is 97% (95% CI: 89–100%). The IgG4
classifier was developed entirely in the training and valida-
tion sets, yet it performed extremely well in the test set. The
AUC for a test is the probability that a random participant
from the disease group (patients) has a higher value than a
randomly selected participant from the disease-free group
(healthy controls). Our results indicate that with 95% CI, the
AUC for IgG4 is higher than 0.94. This constitutes strong
evidence that IgG4 is a reliable predictor.
Figure 1 shows smooth density plots of IgG and IgG
subclass anti-Dsg1 index values (FS sera (red line) and
Table 1. Descriptive statistics for IgG and IgG
subclass index values
FS cases Healthy controls
N Mean Median IQR SD N Mean Median IQR SD
IgG1 214 232.1 73.2 233.1 419.6 261 50.3 0 2.4 206.1
IgG2 214 50.7 0.3 49.9 113.7 261 26.5 2.5 29.7 59.6
IgG3 214 10.6 5.5 9.6 15.0 261 4.5 1.7 3.5 9.2
IgG4 214 76.5 69.0 79.1 53.7 261 1.6 0 1.2 4.6
IgG 209 79.6 88.0 35.8 32.5 250 2.4 0 0 11.7
FS, fogo selvagem; IQR, interquartile range.
Negative index values were replaced by 0 before obtaining these
summaries.
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healthy donor sera (blue line)). The cut point of 6.43 chosen
for IgG4 corresponds to a value of 2 on the x axis. It is clear
that IgG4 anti-Dsg1 autoantibody index values produce the
best separation between control and FS sera.
Positive and negative predictive values of the IgG4-based
predictor
The accuracy of predictions generated by a given classifier in
a population depends not only on its sensitivity and
specificity, but also on the prevalence of disease in that
population (Medina, 1999). Two important measures in that
regard are the PPV and the NPV. The PPV is the probability
that a participant classified as a case does indeed have the
disease. The NPV is the probability that a participant
classified as a non-case is actually disease-free. Table 3
shows how PPV and NPV depend on prevalence for a
diagnostic test with sensitivity 92% and specificity 97%,
which are the estimates for the IgG4-based classifier
developed above. In a population such as that of Limao
Verde with 3% prevalence, a randomly drawn participant has
a 3% chance, or prior probability, of having FS. However, if
that participant tests positive, the disease probability (PPV)
goes up to nearly 49%. Similarly, a random participant from
Limao Verde has a 97% of being disease-free. If that
participant tests negative, the probability (NPV) of being
disease-free goes up to 99.7%.
To compare IgG4 with other potential markers, sensitivity
and specificity for IgG, IgG1, and IgG1þ IgG4 were
estimated from the test set (n¼ 118). These sensitivity and
specificity estimates differ from those in Table 2, which were
obtained from the validation set. Table 3 shows the
corresponding PPV and NPV for IgG1 (sensitivity: 72%,
specificity: 80%), IgG (sensitivity: 87%, specificity: 91%), and
the combination of IgG1þ IgG4 (sensitivity: 89%, specificity:
94%) for the population of Limao Verde. The PPVs for IgG1
was 10%, for IgG was 23%, and for the combination of
IgG1þ IgG4 was 31% are lower than those of IgG4 anti-
Dsg1.
Assessing the performance of the IgG4-based predictor
The performance of the classifier was evaluated in three
additional sets of individuals:
(a) FS cases from Limao Verde during the preclinical and
clinical phases of the disease. We have collected 11 FS cases
for whom sera were available before they developed frank
clinical FS. Some donors had several preclinical samples. The
IgG4-based classifier found that 5 of the 11 cases (45%) had
serological features of FS before developing clinical disease
(cases 1, 3, 6, 9, and 11 of Table 4). The duration of the
preclinical follow-up in each of the 11 cases is also presented
in Table 4. The transition from preclinical to disease stage
lasted 1 year (one case), 2 years (three cases), 3 years (one
case), 4 years (one case), 7 years (three cases), and 10 years
(two cases). The total IgG anti-Dsg1 index values are also
included in Table 4. In 8 of the 11 cases the IgG anti-Dsg1
index values were positive. The five IgG4-positive cases were
also positive for total IgG anti-Dsg1. The sera of three cases
(nos. 7, 8, and 10) were positive for IgG anti-Dsg1 but
negative for IgG4, indicating the different sensitivities and
specificities of the total IgG and IgG4 anti-Dsg1 assays.
The 11 cases that underwent the transition of preclinical to
clinical FS were further analyzed by comparing their
serological features (IgG and IgG4 anti-Dsg1 autoantibodies)
with a group of age-matched and sex-matched normal
individuals from Limao Verde, known to have IgG anti-
Dsg1 autoantibodies for the past 3–5 years and normal skin.
The IgG4 classifier was positive in four of these individuals;
three of them are relatives of one FS patient and maybe
Table 2. Prediction models applied to the training set*
(AUC, sensitivity, and specificity derived from
validation set**)
Predictors AUC Sensitivity Specificity
IgG1 0.78 0.74 0.78
IgG2 0.51 0.45 0.54
IgG3 0.81 0.81 0.68
IgG4 0.96 0.89 0.94
IgG 0.92 0.81 1.00
IgG1 and IgG2 0.80 0.72 0.78
IgG1 and IgG3 0.84 0.72 0.78
IgG1 and IgG4 0.97 0.91 0.95
IgG1 and IgG 0.91 0.81 1.00
IgG2 and IgG3 0.81 0.85 0.68
IgG2 and IgG4 0.96 0.91 0.95
IgG2 and IgG 0.94 0.83 1.00
IgG3 and IgG4 0.96 0.89 0.92
IgG3 and IgG 0.95 0.81 1.00
IgG4 and IgG 1.00 0.83 1.00
IgG1, IgG2, and IgG3 0.84 0.72 0.78
IgG1, IgG2, and IgG4 0.96 0.92 0.94
IgG1, IgG2, and IgG 0.94 0.83 1.00
IgG1, IgG3, and IgG4 0.97 0.91 0.94
IgG1, IgG3, and IgG 0.94 0.81 1.00
IgG1, IgG4, and IgG 1.00 0.92 0.94
IgG2, IgG3, and IgG4 0.97 0.83 1.00
IgG2, IgG3, and IgG 0.95 0.83 1.00
IgG2, IgG4, and IgG 1.00 0.87 1.00
IgG3, IgG4, and IgG 1.00 0.85 1.00
IgG1, IgG2, IgG3, and IgG4 0.97 0.92 0.95
IgG1, IgG2, IgG3, and IgG 0.95 0.83 1.00
IgG2, IgG3, IgG4, and IgG 1.00 0.87 1.00
IgG1, IgG2, IgG4, and IgG 1.00 0.83 1.00
IgG1, IgG3, IgG4, and IgG 1.00 0.87 1.00
IgG1, IgG2, IgG3, IgG4, and IgG 1.00 0.87 0.98
AUC, area under the curve.
*Each model was estimated from the training set (n=239).
**Parameter estimates were then applied to the validation set (n=118) to
estimate the model’s AUC, sensitivity, and specificity.
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genetically predisposed. We are following these individuals
closely for evidence of FS.
(b) Sera from Japanese patients with PV and PF. Sera from
20 mucosal PV patients, which were known to contain only
anti-Dsg3 autoantibodies, were classified as normal sera by
the IgG4 anti-Dsg1 classifier. In contrast, the sera of 17 of 20
mucocutaneous PV (mcPV) and 18 of 20 PF were classified as
having features of FS as they possess anti-Dsg1 autoantibo-
dies. The sera of Japanese PF patients contain anti-Dsg1
autoantibodies, predominantly IgG4 (data not shown). More-
over, the sera of mcPV patients contain a combination of anti-
Dsg1 and anti-Dsg3 autoantibodies.
(c) Sera from three Limao Verde cohorts (2005 data). The
IgG4-based classifier was applied to the sera of 96
individuals, members of the three cohorts from the Limao
Verde Reservation under study since 2005, when the initial
evaluation was performed and serum samples were obtained.
The IgG4 classifier identified 21 individuals (22%) with
serological features of FS: 6 of 34 individuals (17.6%) in
cohort 1 were positive, 6 of 39 (15.3%) in cohort 2 were also
positive as well as 9 of 24 (37.5%) in cohort 3 (Table 5). In
addition, the same donors show the following percentages of
total IgG anti-Dsg1 autoantibodies: cohort 1 (1/34; 2.9%),
cohort 2 (3/41; 7.3%), and cohort 3 (7/24; 29%) (Diaz et al.,
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Figure 1. Smooth density plots of index values of anti-Dsg1 IgG subclasses and IgG in FS patients (red lines) and healthy donors (blue lines). Negative index
values were converted to zero before applying the log transformation.
Table 3. PPV and NPV for IgG4, IgG1, IgG and IgG1+IgG4 anti-Dsg1 tests with different sensitivities and
specificities applied to populations with various prevalence of disease
IgG
(Sens=87%, Spec=91%)
IgG1
(Sens=72%, Spec=80%)
IgG4
(Sens 92%, Spec=97%)
IgG1+IgG4
(Sens=89%, Spec=94%)
Prevalence (%) PPV NPV PPV NPV PPV NPV PPV NPV
0.1 0.00958 0.99986 0.00359 0.99965 0.02978 0.99992 0.01463 0.99988
1 0.08896 0.99856 0.03509 0.99648 0.23650 0.99917 0.13031 0.99882
31 0.23016 0.99560 0.10019 0.98929 0.48677 0.99746 0.31449 0.99639
10 0.51786 0.98438 0.28571 0.96257 0.77311 0.99092 0.62238 0.98716
20 0.70732 0.96552 0.47368 0.91954 0.88462 0.97980 0.78761 0.97158
80 0.97479 0.63636 0.93506 0.41667 0.99191 0.75194 0.98343 0.68116
90 0.98864 0.43750 0.97006 0.24096 0.99639 0.57396 0.99257 0.48705
99 0.99896 0.06604 0.99720 0.02805 0.99967 0.10911 0.99932 0.07946
99.9 0.99990 0.00696 0.99972 0.00285 0.99997 0.01199 0.99993 0.00848
The specificty and sensitivity derived from the test set (25% of the total data set) as described in Methods and Results.
PPV, positive predictive value; NPV, negative predictive value
1The Amerindian reservation of Limao Verde, Brazil exhibits a prevalence of Fogo Selvagem of B3%.
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2008). From the 21 cohort members showing positive IgG4
anti-Dsg1 autoantibodies, 12 had IgG4 autoantibodies
alone (57%) and 9 had a combination of IgG and IgG4
autoantibodies (42.8%). Only 2 individuals outside the 21
were positive for IgG anti-Dsg1 alone. The remaining 75
healthy cohort members exhibited negative IgG anti-Dsg1
autoantibodies. These results demonstrate the higher sensi-
tivity of the IgG4 classifier to detect anti-Dsg1 autoantibodies.
It is interesting that a member of cohort three classified as FS
by our IgG4 predictor (individual JDM) has developed
clinical FS in 2005.
DISCUSSION
The development of an autoimmune disease is one of the
fundamental enigmas of immunology. Many genetic and
environmental factors appear to play a role, making it difficult
to fulfill Koch’s criteria for any of these diseases. Some of the
advantages that an organ-specific autoimmune disease such
as FS (which is epidermal-specific) offers to research in
autoimmunity are related to the fact that anti-Dsg1 auto-
antibodies are pathogenic and the self-antigen, Dsg1, is fully
characterized. Dissection of the underlying mechanisms
involved in autoantibody formation is a difficult task because
Table 4. IgG and IgG4 anti-Dsg1 autoantibodies in 11 FS cases during the preclinical and clinical stage of the
disease
1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Preclinical
(years)
Case 1 IgG 94.34 Unavailable 69.92 2
FS-27 IgG4 95.73 Unavailable 87.66
Case 2 IgG 50.08 Unavailable Unavailable 70.76 3
FS-29 IgG4 1.49 Unavailable Unavailable 31.5
Case 3 IgG 56.63 Unavailable 27.38 2
FS-31 IgG4 9.2 Unavailable 17.75
Case 4 IgG 108.03 Unavailable 104.18 2
FS-32 IgG4 3.2 Unavailable 24.79
Case 5 IgG 30.02 Unavailable Unavailable Unavailable 50.76 4
FS-33 IgG4 1.29 Unavailable Unavailable Unavailable 59.12
Case 6 IgG 68.99 121.01 Unavailable Unavailable 27.83 Unavailable ND Unavailable 45.07 45.85 4.17 10
FS-45 IgG4 6.87 7.04 Unavailable Unavailable 3.99 Unavailable 0.65 Unavailable 26.36 16.74 18.84
Case 7 IgG 8.88 Unavailable Unavailable 19.98 Unavailable 25.87 Unavailable ND 49.9 31.10 103.42 10
FS-46 IgG4 1.33 Unavailable Unavailable 0.22 Unavailable 12.56 Unavailable 0.17 0.7 32.83 28.76
Case 8 IgG 17.66 Unavailable Unavailable Unavailable Unavailable Unavailable Unavailable 37.52 7
FS-37 IgG4 1.38 Unavailable Unavailable Unavailable Unavailable Unavailable Unavailable 12.42
Case 9 IgG 73.06 Unavailable Unavailable Unavailable 84.31 Unavailable Unavailable 136.63 7
FS-38 IgG4 33.29 Unavailable Unavailable Unavailable 96.02 Unavailable Unavailable 137.83
Case 10 IgG 88.01 Unavailable Unavailable Unavailable Unavailable Unavailable Unavailable 27.21 7
FS-39 IgG4 0.46 Unavailable Unavailable Unavailable Unavailable Unavailable Unavailable 11.26
Case 11 IgG 71.89 169.5 1
BA1-1 IgG4 16.09 82.48
Positive IgG4 index value: 46.43.
Positive IgG index value: 411.34.
FS, fogo selvagem; ND, not determined.
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in many instances it is not possible to differentiate between
the pathogenic autoantibody response and a normal back-
ground (natural) immune response.
Importantly, IgG autoantibodies against Dsg1 are
detected not only in FS patients but also in a significant
number of healthy individuals living in an endemic region
such as Limao Verde (Hans-Filho et al., 1996; Diaz et al.,
2008). In this settlement, we have witnessed the transition
from preclinical to clinical stage of the disease (Warren et al.,
2000, 2003; Li et al., 2003; Diaz et al., 2008). The challenge
therefore is to develop assays to detect the earliest serological
markers of FS during the preclinical stage. As shown in this
study, we have developed a classifier/predictor by analyzing
the IgG and the four IgG subclass anti-Dsg1 autoantibody
response in a large data set derived from FS patients and
healthy controls (Table 1) using a sensitive and specific Dsg1
ELISA for IgG and each IgG subclass.
A set of 475 serum samples were tested for IgG and IgG
subclass anti-Dsg1 and were divided at random into a
training set (N¼ 239), a validation set (N¼118), and a test set
(N¼118) to select a prediction model and to assure unbiased
estimation of classification accuracy. The best classifier
involves only IgG4 with an estimated AUC of 0.97 (95%
CI: 0.94–1.00), sensitivity of 92% (95% CI: 82–98%), and
specificity of 97% (95% CI: 89–100%) (Table 3 and Figure 1).
The sensitivity and specificity for the IgG assay for anti-Dsg1
autoantibodies were 5% and 6% lower than those of IgG4
predictor. The PPV and NPV of the classifier, when applied in
a population such as the Limao Verde Reservation with 3%
prevalence, were calculated. It is estimated that an individual
classified as positive has a 49% chance of having FS whereas
a participant classified as negative has a 99.7% probability of
being disease-free (Table 3). The PPVs for IgG1 (10%), IgG
(23%), and IgG1þ IgG4 (31%) anti-Dsg1 autoantibodies
were lower than IgG4. Although the IgG anti-Dsg1 test also
performed well as a serological marker of FS (Table 2 and
Figure 1), the AUC of IgG (0.92) was lower than the
IgG4 AUC (0.96). In addition, using the sensitivity and
specificity for the IgG and IgG4 assays, and the 3%
prevalence of FS in Limao Verde, we estimated that 8.5%
of the inhabitants of this reservation would have a false-
positive IgG anti-Dsg1 assay. The false-positive tests using the
IgG4 anti-Dsg1 assay, however, would be only 2.9%. Finally,
since normal inhabitants of endemic areas of FS, such as
Limao Verde, possess anti-Dsg1 autoantibodies (Warren
et al., 2000; Diaz et al., 2008), its use as a classifier in these
human settlements would be very limited. In contrast, IgG4
anti-Dsg1 autoantibodies are detected in the sera of
individuals developing FS or during recurrence (Li et al.,
2003; Warren et al., 2003). For similar reasons the IgM anti-
Dsg1 autoantibodies (Diaz et al., 2008) did not perform well
(data not shown).
The IgG4-based classifier was validated further by
analyzing two groups of patients: a group of 11 FS patients
during the preclinical stage of the disease and a group of
60 Japanese PV and PF patients. In the first group, the
classifier predicted FS in 5 of 11 individuals (45%) during
the preclinical stage and in all samples during the clinical
stage of FS (100%). It must be emphasized that this classifier
identifies participants with serological features of FS regard-
less of the presence of active skin disease. We propose
that this IgG4-based classifier is a serological marker of FS
during the preclinical and clinical stages of the disease.
During the preclinical stage, this classifier may show
variations over time because of fluctuations in environmental
antigenic stimulation as observed in cases 6 and 7 in
Table 4. However, once a participant exhibits skin disease,
the classifier will be positive with high probability, provided
that the serum sample is obtained before the initiation of
systemic therapy. Eight of the eleven patients exhibited IgG
anti-Dsg1 autoantibodies during the preclinical stage of FS,
in agreement with the high prevalence of these IgG
autoantibodies in this human settlement. Similarly, a control
group from Limao Verde composed of normal individuals
with positive IgG anti-Dsg1 autoantibodies, matched by
age and sex with the 11 patients in Table 4, includes 4
normal participants with positive IgG4 anti-Dsg1. Three of
these normal individuals were first-degree relatives of a
patient with FS. These individuals have been under close
Table 5. Individuals from Limao Verde, Brazil,
identified as FS cases by the IgG4 predictor
Age (years) IgG4 index values
Cohort 1 (ages 5–10)
C1-1 5.4 7.32
C1-2 5.6 11.17
C1-3 6.3 6.43
C1-4 7.7 7.09
C1-5 8.2 15.17
C1-6 9.7 8.19
Cohort 2 (ages 11–15)
C2-1 10.7 130.62
C2-2 11.1 34.88
C2-3 11.5 40.87
C2-4 11.8 12.36
C2-5 12.4 31.12
C2-6 14.2 57.55
Cohort 3 (ages 16–20)
C3-1 15.1 47.15
C3-2 15.5 25.63
C3-3 15.5 19.89
C3-4 16.8 34.09
C3-5 17.3 121.73
C3-6 17.9 21.29
C3-71 18.4 56.75
C3-8 19.8 52.39
C3-9 20.3 34.68
FS, fogo selvagem.
1Developed FS during the course of study.
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observation for 3–5 years since the collection of serum
samples. We will continue following them for any evidence
of clinical FS.
In the group of 60 Japanese patients, 20 patients with
mucosal PV, possessing only anti-Dsg3 autoantibodies, were
classified as normal donors (because of the absence of anti-
Dsg1 autoantibodies). The IgG4-based classifier performed
well in a group of 20 PF patients, of whom 18 were identified
as cases. In a group of 20 mcPV patients, possessing anti-
Dsg1 and anti-Dsg3 autoantibodies, the classifier predicted
the disease in 17 cases. Hence, the IgG4-based classifier
performed well in the Japanese group of patients with PF and
mcPV as both groups of patients possess anti-Dsg1 auto-
antibodies.
The IgG4-based classifier was also used to test the
members of an ongoing prospective cohort in the Limao
Verde Reservation including 96 donors, aged 5–20 years on
their first evaluation in 2005. The IgG4 classifier identified 21
individuals (22%) with serological features of FS: 6 of 34
individuals (17.6%) in cohort 1 were positive, 6 of 39 (15.3%)
in cohort 2 were also positive as well as 9 of 24 (37.5%) in
cohort 3 (Table 5). The same donors show the following
percentages of total IgG anti-Dsg1 autoantibodies: cohort 1
(1/34; 2.9%), cohort 2 (3/41; 7.3%), and cohort 3 (7/24; 29%)
(Diaz et al., 2008). Interestingly, one member of the third
cohort (JDM), classified as a case, has developed FS in the
course of the study. According to the PPV of the IgG4
classifier, it is estimated that about 50% of these positive
participants from Limao Verde have FS in the preclinical
stage and are at risk to develop clinical disease if the
conditions are appropriate. Similarly, each of the 75
participants identified as normal by the classifier have a
99% chance of being disease-free. Forecasting active clinical
disease in individuals of both groups (positive and negative)
using the classifier is the subject of current investigation in
our laboratory. An ongoing prospective study of these cohorts
will validate further this immunological instrument not only
as an identifier of current FS serology but also as a predictor
of future disease. These cohorts are evaluated clinically every
4 months and serologically every 2 years.
Organ-specific and non-organ-specific autoantibodies
have been reported as diagnostic aids in diseases such as
type I diabetes, thyroiditis, adrenalitis, myasthenia gravis,
systemic lupus erythematosus, and rheumatoid arthritis
(Leslie et al., 2001; Scofield, 2004). Moreover, in some of
these diseases the respective autoantibodies have been
detected years before the onset of clinical disease (Notkins
and Lernmark, 2001; Arbuckle et al., 2003). The value of
autoantibodies as predictors has been reviewed (Arbuckle
et al., 2003; Scofield, 2004) and is well documented in
diabetes (Notkins and Lernmark, 2001). In diabetes, the
presence of autoantibodies against glutamic acid decarboxy-
lase, protein tyrosine phosphatase-like molecule, and insulin
in healthy individuals could predict the development of
disease in more than 70% of first-degree relatives of the cases
in the course of 2–10 years (Notkins and Lernmark, 2001).
This report moves FS into the group of organ-specific
autoimmune diseases where epidermal-specific autoantibo-
dies can be used not only as diagnostic markers of FS but also
as predictors of disease as shown in 6 of 11 FS cases where
preclinical sera were available.
Finally, we are reporting an IgG4-based classifier that is
able to identify a serum as exhibiting features of FS or normal
serum. After the ELISA anti-Dsg1 assay methodology to test
for IgG subclasses reported in this study, we found that IgG4
index values above 6.43 are sufficient to classify a serum
sample as having features of FS. Its usefulness in the
evaluation of PF patients or in endemic forms of PF in other
regions of the world must be validated as FS and the endemic
regions of FS are unique. However, our study suggests that
the IgG4-based classifier can be extremely useful in identify-
ing individuals during the preclinical stage of FS. HLA typing
and the IgG4-based classifier would become powerful tools
for the selection of individuals to undergo close clinical and
serological surveillance. Moreover, as the environmental risk
factor(s) can also be assessed among potential FS patients,
these immunological markers may enhance our ability to
identify these factor(s) involved in triggering the autoimmune
disease in FS.
MATERIALS AND METHODS
Sources of sera
A total of 475 serum samples were tested for IgG subclass anti-Dsg1
in this investigation, 214 from FS cases and 261 from healthy
controls (Table 1). From this set 459 sera were tested for IgG anti-
Dsg1 autoantibodies (209 FS and 250 controls) (Table 1). Sera from
classic cases of FS were collected from six Brazilian hospitals
dedicated to treat these patients: Hospital das Clinicas, Sao Paulo
(Hospital SP), (n¼ 49); Hospital de Doenc¸as Tropicaes, Goiania
(Hospital GO), (n¼ 41); Hospital Adventista do Penfigo, Campo
Grande (Hospital CG) (n¼ 27), Hospital Universitario de Belho
Horizonte, Minas Gerais (Hospital MG) (n¼ 47), Hospital Universi-
tario de Brasilia (Hospital Br (n¼ 47), and Outpatient Clinic,
Cascavel, Parana (Parana (n¼ 3). The FS sera were derived from
patients with widespread skin disease. Clinically, they show super-
ficial blisters and erosions and histologically subcorneal vesicles.
The indirect immunofluorescence studies showed anti-epidermal
ICS autoantibodies in titers above 1:80. FS patients admitted to
Brazilian hospitals with widespread disease comprised individuals
with the generalized forms of the disease as described earlier (Hans-
Filho et al., 1999). They include the bullous exfoliative, the
exfoliative erythrodermic, and forms characterized by generalized
keratotic plaques and nodular lesions. The study was conducted
according to the Declaration of Helsinki Principles. Participants gave
their written informed consent.
Normal human sera were obtained from blood bank donors from
Hospital SP (n¼ 57), BH (n¼ 32), Hospital GO (n¼ 41), and the
University of North Carolina Blood Bank (n¼ 131).
Sera used to validate the IgG4 predictor
(a) Eleven sera from FS patients before and after the onset
of FS.
(b) Sera from Japanese patients with PF and PV (Professor M.
Amagai from Keio University, Tokyo, kindly provided us with
sera from the following groups of patients: Dsg1-positive PF
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(n¼ 20), Dsg3-positive mucosal PV (n¼ 20), and Dsg1-positive,
Dsg3-positive mcPV (n¼ 20)).
(c) Sera from three Limao Verde cohorts.
Currently, we are following three cohorts, all inhabitants of the
Limao Verde Reservation. The first cohort comprises normal donors
of age 5–10 years (n¼ 34); the second, age 11–15 years (n¼ 38); and
the third, age 16–20 years (n¼ 24). The sera were obtained during
the first evaluation of the cohorts in May 2005. These investigations
were approved by the Institutional Review Boards of the University
of North Carolina and the University of Sao Paulo, Brazil.
Production and purification of recombinant Dsg1
A His-tagged recombinant form of Dsg1, encompassing the
extracellular domain of this protein, was generated in the
baculovirus system and purified by nickel affinity chromatography
using the procedure of Ding et al. (1997). Optimum conditions for
this expression system were determined empirically as described by
Liebman et al. (1999). The typical protein yield was 10 mg/ml of
culture supernatant.
IgG and IgG subclass anti-Dsg1 ELISA assays
ELISA plates were coated with 200 ng per well of purified Dsg1 at
4 1C overnight. After washing with Tris-buffered saline containing
3.7mM Ca2þ and 0.05% Tween-20 (TBS/Ca2þ /T-20), the plate was
blocked with 1% BSA in TBS/Ca2þ /T-20 at room temperature for
1 hour. The plate was then incubated with duplicate 1:100 dilution
(for IgG plates) and 1:50 dilution (for IgG subclasses) of serum
samples for 1 hour at room temperature. After washing, the plate
was incubated with a 1:2,000 dilution (for IgG plates) and
1:1,000 dilution (for IgG subclasses) of a mouse horseradish
peroxidase-labeled mAb against human IgG or human IgG1, IgG2,
IgG3, and IgG4 subclasses (Zymed, San Francisco, CA) (Warren
et al., 2003; Diaz et al., 2008). Results were expressed as index
value units as reported by Amagai et al. (1999) and Diaz et al.
(2008). The index value was defined in terms of optical density (OD)
as follows:
Index value ¼ ðTest sampleODÞ  ðNegative controlÞODÞðPositive controlODÞ  ðNegative controlÞODÞ100
Statistical analysis
A logistic regression model (McCullagh and Nelder, 1989) was used
to develop a classifier that predicts case–control status based on IgG
and the four IgG subclass index values. The predictors were defined
as follows: first, negative IgG index values were replaced by 0, then
predictors were computed as x¼ log (IgGþ 1). This removed much
of the skewness in the IgG index values. Thus, x1 through x5 were
derived from IgG1 through IgG4 and total IgG. For the purpose of
developing and evaluating a classification rule, the data set was
divided at random into three parts: a training set, a validation set,
and a test set, containing 50, 25, and 25%, respectively, of cases and
controls. This follows the guidelines given by Hastie et al. (2001).
The following procedure was applied to choose the best model
for prediction. All 31 possible models, containing an intercept and
from 1 to 5 predictors, were considered. Each model was estimated
from the training set. Parameter estimates were then applied to the
validation set to estimate the model’s AUC. For example, the model
‘‘IgG1, IgG2, and IgG3’’ in Table 2 is a logistic regression model
with linear predictor b0þ b1x1þ b2x2þ b3x3. Fitting the model to the
training set yields estimates b0, b1, b2, and b3. A score was then
computed for each participant in the validation set as score¼ b0þ
b1x1þ b2x2þ b3x3. The score was used to compute the AUC as a
measure of the model’s predictive ability. AUC was estimated using
non-parametric methods (Hanley and McNeil, 1982).
Additionally, the score was transformed to the probability
scale by P¼ 1/{1þ exp(score)}. For the purpose of computing
sensitivity and specificity, if P40.45 (equivalent to score above
0.2), the participant was classified as a case, otherwise as a non-
case. Cut points other than 0.45 were evaluated, but 0.45 was
deemed to provide the best tradeoff between sensitivity and
specificity. Sensitivity and specificity were estimated as binomial
proportions. The analysis was carried out using SAS 9.1 and R 2.5
software.
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